Insilico Medicine (“Insilico”), a clinical-stage end-to-end generative artificial intelligence (AI) drug discovery company, has achieved a significant breakthrough in the application of multiple generative AI models and AlphaFold structures for drug discovery.
Pfizer terminates an early-stage STING agonist trial
Pfizer’s pipeline prioritization has now turned to a STING agonist, with an early-stage study termination of the asset, a spokesperson confirmed to Endpoints News. …